PIK3CA and breast carcinoma: With regard to PIK3CA mutations, depicted in Fig. 1E, an intermediate adjMAFs level was seen in CRC as compared to breast cancer (median 0.46, IQR 0.29–0.65; n = 64; P = 0.002) and gynecological malignancies (median 0.27, IQR 0.19–0.40; n = 56; P = 0.05).